GlaxoSmithKline (GSK) Misses Q4 EPS by 26c

GlaxoSmithKline (NYSE: GSK) reported Q4 EPS of GBP0.23, GBP0.26 worse than the analyst estimate of GBP0.49. Revenue for the quarter came in at GBP8.12 billion versus the consensus estimate of GBP9.86 billion.

For earnings history and earnings-related data on GlaxoSmithKline (GSK) click here.

You May Also Be Interested In

• Blue Owl leads $2.4 billion debt deal for Iren data center
• Trilogy Metals signs $35.6M investment deal with U.S. Dept. of War
• IP Strategy Holdings receives Nasdaq noncompliance notice over late 10-Q